Loading...
Dernières publications
-
-
Lotta Plomp, Hortense Chassepot, Dimitri Psimaras, Thierry Maisonobe, Eric Mensi, et al.. Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. The Lancet Regional Health - Europe, 2025, 50, pp.101192. ⟨10.1016/j.lanepe.2024.101192⟩. ⟨hal-05404105⟩
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Péréon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
Chiffres clés
130
Publications avec texte intégral
Open Access
55 %
Mots clés
Autoantibody
Auto‐antibodies
Agalsidase
Anti-interleukin-6
AAV
Inclusion body myositis
Antisynthetase
DM
Anticorps anti-agalsidase
Anti-MDA5
Pharmacology
Antiphospholipid syndrome
Interferon
Anti‐mitochondrial antibodies
Idiopathic inflammatory myopathies
Inflammation
Cancer
Biomarkers
Antisynthétase
Anti-Mi2
IMNM
Interstitial lung disease
AAV vectors
COVID-19
AAV antibody
Autoimmunity
Lysosomal storage diseases
Inflammatory myopathy
Immune checkpoint inhibitors
Acid-alpha-glucosidase
Biomarqueurs
Mass cytometry
Adeno-associated virus vector
Fabry disease
Amyotrophic lateral sclerosis
Humans
Aldosterone
Anti-synthetase syndrome
Female
Anémie hémolytique
Autoantibodies
Auto-antibodies
Analyses multidimensionnelles
Muscle
Anti-MDA5 autoantibodies
Autoimmune diseases
IBM
Cardio-oncology
Deep immune profiling
Machine learning
Aldostérone
Dependovirus/genetics/immunology
AAV vector
Gene therapy
Dermatomyositis
Anti-agalsidase antibodies
Acute Kidney Injury/epidemiology/etiology
Myosites
Antisynthetase syndrome
B-lymphocyte
Adjudication
Immunotherapy
Myocarditis
Skeletal muscle
Antibodies
Aged
Anti‐MDA5
Abnormal movement
Cytokines
Male
Anti-IgE IgG
Middle Aged
Inborn errors of metabolism
Systems biology
AAV humoral immunity
Acetylcholine receptor antibodies
Arthritis
Adeno-associated virus
Prognosis
Myopathy
Adult
Auto-immunité
Amyotrophy
Antibody responses
Adverse drug reactions
Active
Sphingosine-1-phosphate
Myositis
Animals
Polymyositis
Adeno-associated vector
Outcome measures
Anti-drug antibodies
Biomarker
Assisted communication devices
B cell homeostasis
Myositis and muscle disease
Adolescence
Idiopathic inflammatory myopathy
Anticorps spécifique des myosites